MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

finance.yahoo.com · 2026-09-16

On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]

TickrTrends take: MannKind's pursuit of inhaled weight loss treatments represents a significant pivot toward a high-growth market segment, though the company is currently operating at a loss while developing this pipeline. Given TickrTrends' undervalued assessment, investors focused on valuation metrics should monitor whether the company can demonstrate clinical progress and commercial traction that would justify current losses as investment in future revenue generation. The success of this strategy will be critical to determining whether the company's current valuation reflects appropriate risk adjustment for a development-stage asset in a competitive therapeutic area.

Read the full story at finance.yahoo.com →